A pharmaceutical advisory committee in Canada has recommended that Orkambi (lumacaftor/ivacaftor) not be reimbursed for the treatment of cystic fibrosis in patients aged six years and older who are homozygous for the F508del mutation.

The Canadian Agency for Drugs and Technologies in Health (CADTH) provides research and analysis to healthcare decision makers. Its Canadian Drug Expert Committee issued the recommendation citing “uncertain clinical significance” in the magnitude of ppFEV1 improvement (2.6% to 3.0%) in patients treated with LUM 400 mg every 12 hours/IVA 250 mg every 12 hours (L400/IVA).

Read the full report and rationale at www.cadth.ca